Navigation Links
DNA2.0 and Blue Sky Biotech Announce Strategic Alliance for Bundled Customer Experience From Gene Synthesis to Purified Protein
Date:5/20/2010

Partnership Expands One-Stop Shopping Options so That Scientists Can Focus on Novel Research

(PRWEB) May 20, 2010 -- DNA2.0, the leading gene synthesis and protein engineering company, today announced a strategic alliance with Blue Sky Biotech in order to provide customers with a seamless experience from gene synthesis to protein expression and purification. Blue Sky Biotech is a premium Contract Research Organization (CRO) for research-based drug discovery that is known for its industry-leading protein expression and purification services.

“Our alliance with DNA2.0 provides researchers with a critical advantage to help them pursue innovative medicines for unmet therapeutic needs,” said Norman Garceau, Ph.D., President and CSO of Blue Sky. “The alliance with DNA2.0 enhances our production capacity in molecular biology and provides access to DNA2.0’s patented technologies. By partnering, our clients will be able to save significant time and receive high-quality solutions.”

A cornerstone of modern biotechnology is the ability to express functional recombinant proteins in heterologous hosts. DNA2.0's rapid and efficient custom gene synthesis allows researchers to redesign entire gene sequences to maximize the likelihood of high protein expression, easy genetic manipulation, minimal promoter leakiness and convenient protein purification. Coupled with Blue Sky’s expression and purification expertise, customers can expect to benefit from major efficiencies based on shared technology enhancements as well as integrated production platforms employing DNA2.0’s optimized codon algorithms or protein expression vectors—in a wide range of host systems.

“The combined expertise of DNA2.0 and Blue Sky provides a one-stop solution for research organizations of all sizes,” said Jeremy Minshull, Ph.D., President of DNA2.0 “By focusing on providing high-quality biological reagents, we enable researchers to focus on their areas of expertise.”

While many other gene synthesis companies and CROs offshore production to laboratories in emerging economies of the world with lax IP protection, all orders through DNA2.0 and Blue Sky are produced in the USA, ensuring the greatest security for patented or confidential sequences.

About Blue Sky Biotech, Inc.
Blue Sky Biotech, Inc. is an integrated provider of custom biologicals for biomedical research and drug discovery and is organized into two divisions: BioServices and BioProducts. The BioServices division offers a wide range of custom services spanning Molecular Biology, Eukaryotic and Prokaryotic Protein Expression, Protein Purification, and Assay Development. This suite of pre-clinical services provides our clients with a convenient source of high quality custom research tools. Blue Sky also invests heavily in technology development to improve or enhance its production capabilities, including a proprietary process technology (IKM®) that significantly reduces cycle times and enhances reproducibility of protein production using baculovirus-mediated insect cell expression. The BioProducts division offers high quality biologicals and membrane protein solutions (TDA™ and SmartscreenTM Kits) designed to facilitate drug discovery. The company is a privately held corporation with over 40 staff members. It is located in Worcester, MA. For more information, please visit www.blueskybiotech.com.

About DNA2.0
Founded in 2003, DNA2.0 is the leading synthetic genomics company. It is the fastest provider of synthetic genes, based in the US with a global customer base encompassing academia, government and the pharmaceutical, chemical, agricultural and biotechnology industries. DNA2.0 explores novel applications for synthetic genes and is exploiting the synergy between highly-efficient gene synthesis process and new protein optimization technologies. The tools and applications brought to market by DNA2.0 are transforming biology into an engineering discipline. The company is privately held and is headquartered in Menlo Park, Calif. For more information, please visit www.DNA20.com.

# # #

Read the full story at http://www.prweb.com/releases/2010/05/prweb4026654.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
2. DNA2.0 Launches New Website: Enhanced Design and Free Bioinformatics Tools Demonstrate DNA2.0's Customer Focus
3. RNAi Helps Illuminate the Inner Workings of the Cell Cycle: Synthetic RNAissance™ Genes Created by DNA2.0 Enable Key Research
4. DNA2.0 Introduces Freedom of Expression With a New Family of Bacterial Expression Vect:ors
5. DNA2.0 Awarded US Patents for Breakthrough Gene Optimization Technology -- Company's Unique Algorithm Enables Expression Yields up to 50 Times Greater than Competing Approaches
6. DNA2.0 Unlocks The Secrets Of Optimized Gene Design: Company Identifies Codon Choice Design Principles for Optimal Protein Expression
7. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
10. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
11. Finkelstein Thompson LLP Announces GPC Biotech AG Investigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... , May 19, 2016 ... una sessione orale durante il 52 ° ... n. 8006)    - Le conclusioni dello ... riguarda i pazienti trattati, di cui il 90% presenta una ... sei mesi o più. Il settantadue per cento dei pazienti ...
(Date:5/18/2016)... , ... May 18, 2016 , ... STACS DNA Inc., ... to easily track and report sexual assault kit processing to help them save time ... as pressure escalates for kits to be processed and victims informed of results. Due ...
(Date:5/17/2016)... , May 18, 2016 ... 2.0 prefilled pen following approval by EMA, the European ... leading science and technology company, the new pen version ... an increased level of confidence to patients during use. ... GONAL-f® prefilled pen easier to handle with a larger ...
(Date:5/17/2016)... York, NY (PRWEB) , ... May 17, 2016 , ... ... Month, buildings, bridges, and monuments across the globe will show their support in the ... NF. , Neurofibromatosis, NF, is a genetic disorder that causes tumors to grow ...
Breaking Biology Technology:
(Date:3/14/2016)... , March 14, 2016 NXTD ) ... mobile commerce market, announces the airing of a new series ... the week of March 21 st .  The commercials will ... its popular Squawk on the Street show. --> ... the growing mobile commerce market, announces the airing of a ...
(Date:3/11/2016)... http://www.apimages.com ) - --> http://www.apimages.com ) - ... ( http://www.apimages.com ) - Germany . The ... refugee identity cards. DERMALOG will be unveiling this device, and a ... next week.   --> Germany . ... new refugee identity cards. DERMALOG will be unveiling this device, and ...
(Date:3/10/2016)... --> --> ... and Access Management Market by Component (Provisioning, Directory Services, ... Organization Size, by Deployment, by Vertical, and by Region ... market is estimated to grow from USD 7.20 Billion ... a Compound Annual Growth Rate (CAGR) of 12.2% during ...
Breaking Biology News(10 mins):